Medroxyprogesterone and Thrombosis Risk

Evidence for Thrombotic Risk

Injectable DMPA is associated with a significantly higher risk of venous thromboembolism (VTE) compared to other progestin-only contraceptives, with a relative risk of 2.67 (95% CI 1.29-5.53) 1
The American College of Rheumatology specifically recommends against using DMPA in patients with antiphospholipid antibodies due to concerns about thrombogenicity 2, 1
The American Heart Association/American College of Cardiology guidelines state that injectable DMPA should be avoided in women with chronic coronary disease or previous stroke due to increased thrombosis risk 3, 4

The specific progestin and its serum level affect thrombosis risk, with some progestins having more prothrombotic effects than others 1

Progestin-only pills and levonorgestrel IUDs do not appear to increase VTE risk, with relative risks of 0.90 (95% CI 0.57-1.45) and 0.61 (95% CI 0.24-1.53), respectively 1
The copper IUD is a highly effective non-hormonal alternative that does not increase VTE risk 1

The risk of thrombosis with medroxyprogesterone is particularly concerning in patients with positive antiphospholipid antibodies 2, 1
The risk of thrombosis with medroxyprogesterone is particularly concerning in patients with chronic coronary disease or previous stroke 3, 4
The risk of thrombosis with medroxyprogesterone is particularly concerning in patients with history of previous thrombotic events 1
The risk of thrombosis with medroxyprogesterone is particularly concerning in patients with congenital heart disease with high thrombotic risk (e.g., cyanosis, Fontan physiology) 5

For women requiring contraception who have risk factors for thrombosis, the copper IUD (non-hormonal) is a preferred option 1
For women requiring contraception who have risk factors for thrombosis, levonorgestrel IUD is a preferred option 1
For women requiring contraception who have risk factors for thrombosis, progestin-only pills are a preferred option 1
Women with chronic coronary disease should avoid both combined hormonal contraceptives and injectable DMPA 3, 4

Progestins can create a procoagulant environment with a decrease in antithrombin III and protein S levels 6

Medroxyprogesterone is not recommended for patients with cyanotic congenital heart disease, prior Fontan procedure, atrial fibrillation, or pulmonary arterial hypertension due to increased thrombosis risk 7

Levonorgestrel-containing IUDs or barrier methods are recommended contraceptive methods for women with cyanotic congenital heart disease and pulmonary arterial hypertension 7
Estrogen-containing contraceptives are generally not recommended for patients at risk of thromboembolism 7

Patients on medroxyprogesterone should be monitored for signs of thrombosis, including leg pain/swelling, chest pain, shortness of breath, or neurological symptoms 6
Meticulous prophylaxis for deep venous thrombosis, including early ambulation and compression stockings, is recommended for patients at high risk of thrombosis 7
Full anticoagulation should be considered for high-risk patients requiring medroxyprogesterone therapy 7

Synthetic progestins are associated with pro‑thrombotic hemostatic alterations, including increased activity of coagulation factor VII, elevated D‑dimer levels, and higher concentrations of prothrombin fragment F1.2, indicating enhanced clot formation potential【8】.

Women who carry inherited thrombophilic mutations such as Factor V Leiden or the prothrombin 20210A variant experience a markedly greater risk of venous thromboembolism when using hormone therapy that contains synthetic progestins【8】.